360 results
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
6 May 09
Ligand Pharmaceuticals Announces First Quarter Results
12:00am
demonstrate the operating leverage in our business model, and the Company’s potential for delivering strong cash flow over the long-term and driving shareholder … guidance for 2009, that Ligand will deliver strong cash flow over the long term, that Ligand’s 2009 revenues will be driven by royalty payments related
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
31 Jul 08
Ligand Pharmaceuticals Announces Second Quarter Results
12:00am
in hepatitis C, a Phase I trial in sarcoma and Phase II trials in chemotherapy-induced thrombocytopenia, and expects MAA and NDA submissions for the long-term treatment …
Property and equipment, net
Long-term portion of co-promote termination asset
Other assets
Liabilities and Stockholders' Equity
Accounts payable
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
2 May 12
Ligand Pharmaceuticals Reports First Quarter Results
12:00am
, that Ligand will deliver strong cash flow over the long term, that Ligand will realize the expected benefits of the acquisition of CyDex, that Ligand’s … and other identifiable intangible assets
Long-term portion of co-promote termination asset
Other assets
Total Assets
Liabilities and Stockholders’ Equity
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
10 May 11
Ligand Pharmaceuticals Reports First Quarter Results
12:00am
cash flow over the long term, that Ligand will realize the expected benefits of the acquisition of CyDex, that Ligand's 2011 revenues at the levels …
Long-term portion of co-promote termination asset
Other assets
Liabilities and Stockholders' Equity
Accounts payable and accrued liabilities
Current
8-K/A
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
25 Sep 98
Form 8-K, Amendment No. 1
12:00am
................................... 10,000,000 10,000,000
Long-term obligation............................... 1,450,000 … --
Amortization of discount on long-term debt........... 171,903 --
Extraordinary item
8-K
EX-99.1
g5p 4mfeq6n3j
7 Feb 12
Ligand Reports Fourth Quarter and Full Year 2011 Financial Results
12:00am
8-K
EX-99.1
tsaqtov6txjilie4ef72
9 Nov 10
Ligand Pharmaceuticals Announces Third Quarter Results
12:00am
8-K
EX-99.1
z2yk1qe1eb6h8tjcpgc
8 Aug 11
Ligand Pharmaceuticals Announces Second Quarter Results
12:00am
8-K
EX-99.1
7n3gr 26241
9 Feb 10
Ligand Announces Fourth Quarter and Full Year 2009 Consolidated Financial Results
12:00am
8-K
EX-99.1
wdssmfxd717b42ke
30 Oct 13
Ligand Reports Third Quarter Financial Results
12:00am
8-K
EX-99.1
xbxmky74u1j248sau9v
15 Feb 11
Ligand Announces Fourth Quarter and Full Year 2010 Consolidated Financial Results
12:00am
8-K
EX-99.1
pazjjuhoh2y572a4xs
3 Aug 09
Ligand Pharmaceuticals Announces Second Quarter Results
12:00am
8-K
EX-99.1
efr r8h7lf76nwp
5 May 04
Financial statements and exhibits
12:00am
425
w6gcco36sg4gqj
6 Nov 08
Business combination disclosure
12:00am
8-K
EX-99.1
1spxr
1 May 08
Ligand Pharmaceuticals Announces First Quarter Results
12:00am
8-K
EX-99.1
rs331316hk dyob13
20 Feb 08
Ligand Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
12:00am
8-K
EX-99
zddz8ec63j ip8
8 Nov 07
Results of Operations and Financial Condition
12:00am